Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

APRiCOT-P (Apricoxib in Combination Oncology Treatment - Pancreas): Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Gemcitabine and Erlotinib in the Treatment of Patients With Advanced Pancreatic Cancer

NCT00709826 is registered in ClinicalTrials.gov with Tragara Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00709826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00709826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
APRiCOT-P (Apricoxib in Combination Oncology Treatment - Pancreas): Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Gemcitabine and Erlotinib in the Treatment of Patients With Advanced Pancreatic Cancer
Lead sponsor
Tragara Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
May 31, 2011
Enrollment
109 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer, pancreatic cancer